The broad‐spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF‐mutant melanoma cells in combination with other signaling pathway inhibitors

Publisher: John Wiley & Sons Inc

E-ISSN: 1755-148x|28|4|417-430

ISSN: 1755-1471

Source: PIGMENT CELL & MELANOMA RESEARCH, Vol.28, Iss.4, 2015-07, pp. : 417-430

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content